[go: up one dir, main page]

EA201071317A1 - ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ - Google Patents

ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ

Info

Publication number
EA201071317A1
EA201071317A1 EA201071317A EA201071317A EA201071317A1 EA 201071317 A1 EA201071317 A1 EA 201071317A1 EA 201071317 A EA201071317 A EA 201071317A EA 201071317 A EA201071317 A EA 201071317A EA 201071317 A1 EA201071317 A1 EA 201071317A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
formula
indoal
tetrahydrocyclopent
modulators
Prior art date
Application number
EA201071317A
Other languages
English (en)
Other versions
EA019713B1 (ru
Inventor
Прабхакар Кондаджи Джадхав
Венкатеш Кришнан
Еуибонг Джемс Ким
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201071317A1 publication Critical patent/EA201071317A1/ru
Publication of EA019713B1 publication Critical patent/EA019713B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В настоящем изобретении предложено соединение формулыили фармацевтически приемлемая соль указанного соединения; фармацевтические композиции, содержащие соединение формулы (I) в сочетании с подходящим носителем, разбавителем или наполнителем; и способы лечения или профилактики физиологических нарушений, в частности снижения костной массы, остеопороза, остеопении, снижения мышечной массы или мышечной силы или эректильной дисфункции, включающие введение соединения формулы (I) или фармацевтически приемлемой соли указанного соединения.
EA201071317A 2008-05-16 2009-05-14 ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ EA019713B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5372208P 2008-05-16 2008-05-16
PCT/US2009/043875 WO2009140448A1 (en) 2008-05-16 2009-05-14 Tetrahydrocyclopenta[b]indole androgen receptor modulators

Publications (2)

Publication Number Publication Date
EA201071317A1 true EA201071317A1 (ru) 2011-06-30
EA019713B1 EA019713B1 (ru) 2014-05-30

Family

ID=40847864

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071317A EA019713B1 (ru) 2008-05-16 2009-05-14 ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ

Country Status (18)

Country Link
US (1) US8486943B2 (ru)
EP (1) EP2297100B1 (ru)
JP (1) JP5603327B2 (ru)
KR (1) KR101278788B1 (ru)
CN (1) CN102026974B (ru)
AU (1) AU2009246348B2 (ru)
BR (1) BRPI0912394A2 (ru)
CA (1) CA2724629C (ru)
CY (1) CY1113341T1 (ru)
DK (1) DK2297100T3 (ru)
EA (1) EA019713B1 (ru)
ES (1) ES2396612T3 (ru)
HR (1) HRP20120917T1 (ru)
MX (1) MX2010012436A (ru)
PL (1) PL2297100T3 (ru)
PT (1) PT2297100E (ru)
SI (1) SI2297100T1 (ru)
WO (1) WO2009140448A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009105214A2 (en) 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
HUE061499T2 (hu) 2014-03-28 2023-07-28 Univ Duke Mellrák kezelése szelektív ösztrogénreceptor-módosítók alkalmazásával
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
AU2017281038B2 (en) 2016-06-22 2021-09-09 Ellipses Pharma Ltd AR+ breast cancer treatment methods
US20180185347A1 (en) * 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
CN110191707A (zh) 2017-01-05 2019-08-30 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
US20230255933A1 (en) * 2020-07-06 2023-08-17 Crescenta Biosciences Antiviral use of fabp4 modulating compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) * 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
JP2005527464A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
WO2003097598A1 (fr) * 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Composé comprenant un antagonisme du récepteur de pdg2
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
AU2005226759A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
EP1828195A2 (en) 2004-11-23 2007-09-05 PTC Therapeutics, Inc. Substituted phenols as active agents inhibiting vegf production
AR052674A1 (es) * 2005-02-17 2007-03-28 Wyeth Corp Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
PL1902026T3 (pl) 2005-06-24 2010-07-30 Lilly Co Eli Pochodne tetrahydrokarbazolu użyteczne jako modulatory receptora androgenowego (SARM)
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators

Also Published As

Publication number Publication date
KR20100132551A (ko) 2010-12-17
CA2724629A1 (en) 2009-11-19
AU2009246348A1 (en) 2009-11-19
PL2297100T3 (pl) 2013-03-29
MX2010012436A (es) 2010-12-06
KR101278788B1 (ko) 2013-06-25
AU2009246348A8 (en) 2010-12-16
EP2297100A1 (en) 2011-03-23
ES2396612T3 (es) 2013-02-22
WO2009140448A1 (en) 2009-11-19
AU2009246348B2 (en) 2012-04-12
CN102026974B (zh) 2013-08-28
BRPI0912394A2 (pt) 2016-07-26
EA019713B1 (ru) 2014-05-30
JP2011520903A (ja) 2011-07-21
EP2297100B1 (en) 2012-10-31
CA2724629C (en) 2014-08-19
HRP20120917T1 (hr) 2012-12-31
US8486943B2 (en) 2013-07-16
DK2297100T3 (da) 2012-12-17
WO2009140448A8 (en) 2010-01-07
CY1113341T1 (el) 2016-06-22
US20110039855A1 (en) 2011-02-17
CN102026974A (zh) 2011-04-20
PT2297100E (pt) 2013-01-24
SI2297100T1 (sl) 2013-02-28
JP5603327B2 (ja) 2014-10-08

Similar Documents

Publication Publication Date Title
EA201071317A1 (ru) ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
ATE457979T1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
SI1891038T1 (sl) Substituirani n-arilpirolodini kot selektivni modulatorji androgenskega receptorja
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
EA200970928A1 (ru) Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения
EA201170922A1 (ru) Производные сульфонамида
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
DK1885333T3 (da) Farmaceutisk formulering af apomorphin til bukkal indgivelse
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
EA201201414A1 (ru) КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
IL206611A0 (en) Novel imidazolinylmethyl aryl sulfonamides
DOP2009000117A (es) Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
MX2009003930A (es) Novedoso cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU